Core A-Pathology Core

核心A(病理学核心)-摘要/摘要 胰腺导管腺癌(PDAC)的研究具有独特的挑战性。 复杂的组织病理学，多种不同类型的肿瘤微环境(TME)，无数的遗传 异常和相关的生物影响，以及组织可获得性和质量的实际限制。我们的 病理团队凭借其在小鼠和人类PDAC方面的深厚专业知识，在 P01成立以来几乎所有实验的病理分析。大体上讲，这些 活动包括评估基因工程小鼠(GEM)，包括具有时间调节、 上皮和/或间质成分的间隔性破坏；肿瘤促进信号的分析 具有细胞类型特异性定位到肿瘤细胞本身或在宿主反应中的途径 TME；TME内细胞成分的鉴定和多维评估；以及交叉 GEM模型和人类肿瘤样本之间观察的物种验证。病理学的核心意志 继续收集、维护、存档和记录所有与人类和小鼠PDAC相关的生物资源。 这些材料包括从原发和转移的人和鼠的PDAC中产生的有机类化合物，以及 注释的低传代PDAC细胞系的资料库。核心A将与该项目密切合作 调查员要实现三个具体目标：一)提供组织学服务和咨询专门知识，包括 对小鼠和人胰腺肿瘤的病理学评估进行集中审查；ii)提供 各种免疫组织化学、免疫荧光和原位免疫组化的基础设施和技术专长 杂交分析和定量图像分析；以及iii)产生、表征和维持有机类化合物 模型，以及用于项目和等位基因的早期传代肿瘤和基质细胞培养 建模与实验治疗核心中的工程学。证明这一核心的进步源于 在前一个周期中建立了&gt；165个PDX和&gt；30个低传代PDAC细胞系。核心A的领导者是 MDACC的王华民博士，以及联合调查员Anirban Maitra博士和Michael Kim-Ben Long-Ben 长期的专业知识，大量的P01合作以及在组织病理学和 人和小鼠PDAC组织的分子评估。核心A将建立在之前的坚实基础上 以及调查人员之间的许多持续互动，以促进P01结果的高度成功。

Core A (Pathology Core) - Abstract/Summary The study of pancreatic ductal adenocarcinoma (PDAC) presents unique challenges given its formidably complex histopathology, the many diverse cell types of the tumor microenvirionment (TME), myriad genetic abnormalities and associated biological impact, and practical limitations of tissue availability and quality. Our pathology team, with its deep expertise in mouse and human PDAC, has played a central and essential role in the pathologic analysis of virtually all experiments of this P01 since its inception. Broadly speaking, these activities include evaluation of genetically engineered mice (GEM), including mice with temporally regulated, compartment-specific disruption in epithelial and / or stromal components; analyses of tumor promoting signaling pathways with cell-type specific localization to either neoplastic cells per se, or within the host response in the TME; identification and multi-dimensional assessments of cellular components within the TME; and the cross- species validation of observations between GEM models and human tumor samples. The Pathology Core will continue to collect, maintain, archive and record all human and mouse PDAC-associated biological resources. These materials include organoids created from primary and metastatic human and mouse PDAC, and a repository of annotated low-passage PDAC cell lines. Core A will work in close collaboration with the Project Investigators to achieve three specific aims: i) to provide histology services and consultative expertise, including centralized review in the pathologic evaluation of mouse and human pancreatic neoplasms; ii) to provide infrastructure and technical expertise for a variety of immunohistochemical, immunofluorescent and in situ hybridization assays with quantitative image analysis; and iii) to generate, characterize and maintain organoid models, as well as early passage tumor and stromal cells cultures for use by the Projects as well as for allele engineering in The Modeling & Experimental Therapeutics Core. A testament to this Core’s progress stems from the creation of >165 PDXs and >30 low passage PDAC cell lines during the previous cycle. Core A’s leader is Dr. Huamin Wang at MDACC, joined by Co-Investigators Drs. Anirban Maitra and Michael Kim- bring long- standing expertise, numerous P01 collaborations and a strong publication record in the histopathological and molecular assessment of human and murine PDAC tissues. Core A will build upon the strong foundation of prior and many ongoing interactions between investigators in order to facilitate a highly successful P01 outcome.